Alendronate inhibits growth of high-grade chondrosarcoma cells

Anticancer Research

Volumn 29, Issue 6, 2009, Pages 1879-1888

  Susa, Michiro ^a,b   Morii, Takeshi ^a   Yabe, Hiroo ^a   Horiuchi, Keisuke ^a   Toyama, Yoshiaki ^a   Weissbach, Lawrence ^c   Hornicek, Francis J ^b   Morioka, Hideo ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c MGR J 1115 ^*

Author keywords

Alendronate; Antiproliferative activity; Apoptosis; Chondrosarcoma

Indexed keywords

ALENDRONIC ACID; MEVALONIC ACID;

ADULT; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE; CELL LOSS; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CHONDROSARCOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOSKELETON; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ALENDRONATE; BLOTTING, WESTERN; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; CHONDROSARCOMA; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; MALE; MIDDLE AGED; PROTEOME; TUMOR CELLS, CULTURED;

EID: 67650908933     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Fletcher C, Unni K and Mertens F (eds.): Pathology and Genetics of Tumours of Soft Tissue and Bone. Lyon, IARC Press 2002.
2. Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD, Golub E and Rodan GA: Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 88: 2095, 1991.
3. Shipman CM, Croucher PI, Russell RG, Helfrich MH and Rogers MJ: The bisphosphonate incadronate(YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res 58: 5294-5297, 1998.
4. Hiraga T, Williams PJ, Mundy GR and Yoneda T: The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases. Cancer Res 61: 4418-4424, 2001. (Pubitemid 32685769)
5. Jagdev SP, Coleman RE, Shipman CM, Rostami HA and Croucher PI: The bisphosphonate, zolendronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer 84: 1126-1134, 2001. (Pubitemid 32448513)
6. Lacema L and Hohneker J: Zoledronic acid for the treatment of bone metastases in patients with breast cancer and other solid tumors. Semin Oncol 30(Suppl 16): 150-160, 2003. (Pubitemid 37433406)
7. Kubo T, Shimose S, Matsuo T, Tanaka K, Yasunaga Y, Sakai A and Ochi M: Inhibitory effects of new bisphosphonate, minedronate, on proliferation and invasion of a variety of malignant bone tumor cells. J Orthop Res 24: 1138-1144, 2006. (Pubitemid 43870875)
8. Te-jen L, Sheng-feng H, Te-mao LI, Lai TJ, Hsu SF, Li TM, Hsu HC, Lin JG, Hsu CJ, Chou MC, Lee MC, Yang SF and Fong YC: Alendronate inhibit cell invasion and MMP-2 secretion in human chondrosarcoma cell line. Acta Pharmacol Sin 28: 1231-1235, 2007. (Pubitemid 47197778)
9. Fisher IE, Rogers MJ, Halasy JM, Luckman SP, Hughes DE, Masarachia PJ Wesolowski G, Russell RG, Rodan GA and Reszka AA: Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci USA 96: 133-138, 1999. (Pubitemid 29036065)
10. Ory B, Heymann MF, Kamijo A, Gouin F, Heymann D and Redini F: Zoledronic acid suppresses lung metastasis and prolongs overall survival of osteosarcoma-bearing mice. Cancer 104: 2522-2531, 2005. (Pubitemid 41691577)
11. Morioka H, Weissbach L, Vogel T, Nielsen GP, Faircloth GT, Shao L and Hornicek FJ: Antiangiogenesis treatment combined with chemotherapy produces chondrosarcoma necrosis. Clin Cancer Res 9(3): 1211-1217, 2003. (Pubitemid 36323731)
12. Lord RA and Roath S: Evaluation and comparison of neutrophil bipolar shape formation with a migration assay. J Clin Pathol 43(4): 342-345, 1990. (Pubitemid 20111790)
13. Shamovsky I, Ivannikov M, Kandel ES, Gershon D, and Nudler E: RNA-mediated response to heat shock in mammalian cells. Nature 440: 556-560, 2006.
14. Benford HL, Frith JC, Auriola S, Mönkkönen J and Rogers MJ: Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonate: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs. Mol Pharmacol 56: 131-140, 1999. (Pubitemid 29309821)
15. Tassone P, Tagliaferri P, Viscomi C, Palimeti C, Caraglia M, D'Alessandro A, Galea E, Goel A, Abbruzzese A, Boland CR and Venuta S: Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro. Br J Cancer 88: 1971-1978, 2003. (Pubitemid 36829676)
16. Van Beek E, Hoekstra M, van de Ruit, Löwik C and Papapoulos S: Structural requirements for bisphosphonate action in vitro. J Bone Miner Res 9: 1875, 1994.
17. Mackie PS, Fisher JL, Zhou H and Choong PF: Bisphosphonate regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line. Br J Cancer 84: 951-958, 2001. (Pubitemid 32385839)
18. Mashima T, Naito M, Noguchi K, Miller DK, Nicholson DW and Tsuruo T: Actin cleavage of CPP-32/apopain during the development of apoptosis. Oncogene 14: 1007-1012, 1997. (Pubitemid 27129244)
19. Heymann D, Ory B, Blanchard F, Heymann MF, Colpeau P, Charrier C, Couillaud S, Thiery JP, Gouin F and Redini F: Enhanced tumor regression and tissue repair when zolendronic acid is combined with ifosfamide in rat osteosarcoma. Bone 37: 74-86, 2005. (Pubitemid 40848420)
20. Ottewell PD, Mönkkönen H, Jones M, Lefley DV, Coleman RE and Holen I: Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. J Natl Cancer Inst 100(16): 1167-1178, 2008.
21. Murayama T, Kawasoe Y, Yamashita Y, Ueno Y, Minami S, Yokouchi M and Komiya S: Efficacy of the third-generation bisphosphonate risedronate alone and in combination with anticancer drugs against osteosarcoma cell lines. Anticancer Res 28(4B): 2147-2154, 2008.